The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury

Area of Science:

• Gastroenterology
• Molecular Biology
• Oncology

Background:

• Ras association domain family protein 1A (RASSF1A) is a known tumor suppressor gene frequently silenced in various cancers.
• The role of RASSF1A in regulating intestinal inflammation and epithelial homeostasis remains largely unexplored.

Purpose of the Study:

• To investigate the function of RASSF1A as a regulator of intestinal inflammation and epithelial repair.
• To elucidate the molecular mechanisms by which RASSF1A influences inflammatory responses and cell death pathways in the context of colitis.

Main Methods:

• Utilized RASSF1A knockout (Rassf1a(-/-)) and intestinal epithelial cell-specific knockout (Rassf1a (IEC-KO)) mouse models.
• Administered dextran sulphate sodium (DSS) to induce colitis and assessed disease severity, intestinal permeability, cytokine production, NFκB activity, and epithelial cell death.
• Investigated proliferation markers (YAP), tyrosine phosphorylation, p73 and p53 accumulation, and apoptosis.
• Examined the effect of the tyrosine kinase inhibitor imatinib/gleevec on disease progression and survival.
• Assessed RASSF1A interactions with Toll-like receptor (TLR) components.

Main Results:

• Rassf1a knockout mice exhibited exacerbated clinical symptoms of inflammatory bowel disease (IBD) following DSS administration, including increased intestinal permeability, heightened cytokine/chemokine production, elevated NFκB activity, and significant epithelial cell injury and death.
• Epithelial repair was impaired in DSS-treated Rassf1a knockout mice, with reduced YAP-driven proliferation. Tyrosine phosphorylation of YAP correlated with increased nuclear p73, Bax-driven cell death, and p53 accumulation, leading to enhanced apoptosis and reduced survival.
• Imatinib/gleevec treatment improved survival in DSS-treated Rassf1a knockout mice but did not inhibit p53 accumulation, highlighting the critical role of p53-dependent cell death.
• RASSF1A was found to associate with membrane proximal TLR components, suggesting a role in restricting TLR-driven NFκB activation.

Conclusions:

• RASSF1A is a critical negative regulator of intestinal inflammation and a key protector of intestinal epithelial homeostasis.
• Loss of RASSF1A leads to uncontrolled TLR-driven NFκB activation, inflammation-induced DNA damage, YAP tyrosine phosphorylation, p53 accumulation, and ultimately, impaired epithelial repair and increased apoptosis.
• Targeting RASSF1A-mediated pathways, particularly the interplay between TLRs, YAP, and p53, offers potential therapeutic strategies for inflammatory bowel disease.